(Q24241412)

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Hypodermoclysis for control of dehydration in terminal-stage cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Opioid effectiveness and side effects in chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Management of opioid-induced gastrointestinal effects in patients receiving palliative care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Sedation for terminally ill patients with cancer with uncontrollable physical distress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Novel approaches to the treatment of nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Haloperidol Parenterally for Treatment of Vomiting and Nausea from Gastrointestinal Disorders in a Group of Geriatric Patients: Double-Blind, Placebo-Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

[Benefit and risk of high-dose metoclopramide in comparison to high-dose haloperidol or triflupromazine in cisplatin-induced vomiting].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Tolerability of the compound ABHR in hospice patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Recruiting patients into a primary care based study of palliative care: why is it so difficult?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Benzodiazepines and related drugs for insomnia in palliative care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Symptom burden in the last week of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Clinical management of neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

7 January 2021

A randomised cross-over trial of antiemetic therapy for platinum-based chemotherapy. Improved control with an intensive multiagent regimen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

7 January 2021

Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

7 January 2021

Use of clinical pictures in the management of nausea and vomiting: a prospective audit

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

7 January 2021

Prolonged extra-pyramidal side effects after discontinuation of haloperidol as an antiemetic

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

7 January 2021

A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD006271.PUB2

1 reference

7 January 2021